CMS-121

CMS-121

25mg - 60 Capsules
$99.00
Skip to product information
CMS-121

CMS-121

$99.00
Volume

CMS121 — ACC1 & FASN Modulator (GeroneuroProtective Small-Molecule)

CMS121 is a synthetic derivative of the flavonoid Fisetin, developed for research into neurodegeneration, metabolic dysfunction and age-related lipid dysregulation. It has shown promising activity in pre-clinical models involving lipid synthesis suppression, oxidative stress reduction and cognitive preservation. 

Identifiers
  • Synonyms: CMS-121, CMS121, CMS 121
  • CAS No: 1353224-53-9 
  • Formula / MW: C20H19N O3 • ~321.37 g∙mol⁻¹ 
  • Primary targets: Acetyl‑CoA Carboxylase 1 (ACC1) and Fatty Acid Synthase (FASN) — key lipogenesis enzymes. 
How It Works (Plain English)
  • CMS121 inhibits ACC1 and FASN, slowing the creation of new fatty acids inside cells and reducing the pool of lipids that can undergo harmful peroxidation. 
  • This leads to less oxidative damage from lipid-peroxides, improved mitochondrial and cellular health, and a reduction in inflammatory/age-related stress signaling. 
  • Because excess lipid synthesis and peroxidation are implicated in neuro-degeneration, metabolic disease and ageing, CMS121 is used to explore these mechanisms. 
Why Researchers Use It
  • To investigate how reducing lipogenesis impacts memory decline, oxidative damage and lipid peroxidation in neurodegeneration models. 
  • To explore metabolic and aging-related endpoints such as obesity, inflammation, insulin resistance and organ-damage markers. 
  • To assess mitochondrial markers, lipidomics, and cellular resilience in translational ageing studies. 

Key Studies — What Was Tested, What Changed, Why It Matters

Transgenic Alzheimer’s Model: Lipid Peroxidation & Cognition
  • What was tested: Mice (APPswe/PS1ΔE9) with Alzheimer-like pathology treated with CMS121 (~34 mg/kg/day for 3 months). 
  • What changed: Cognitive performance restored to wild-type levels; lipid-peroxidation markers (4-HNE adducts) and 15-LOX2 levels reduced in hippocampus. 
  • Why it matters: Demonstrates the link between lipid metabolism and neuro-degeneration and positions CMS121 as a tool for studying this axis. 
Metabolic & Aging Models: Obesity, Liver + Kidney Protection
  • What was tested: Aged/diet-induced metabolic models treated with CMS121 (6 months diet containing CMS121) assessing weight gain, glucose/lipid parameters, liver/kidney.
  • What changed: ~40% less weight gain, improved glucose/lipid profiles, lowered hepatic inflammatory markers, improved kidney mitochondrial proteins. 
  • Why it matters: Suggests lipogenesis inhibitors may protect peripheral organs and entire metabolic system, not just brain. 

Potential Research Applications

Neurodegeneration & Ageing

  • Alzheimer’s-models, oxidative stress, lipid peroxidation, cognitive assays.

Metabolic & Obesity Research

  • Age-related obesity, insulin resistance, hepatic steatosis, kidney damage models.

Lipidomics & Mitochondrial Biology

  • Lipid-synthesis suppression, mitochondrial markers (TFAM, Nrf1), lipid peroxidation readouts.

Synergistic / Comparator Compounds

BAM15 (Mitochondrial Uncoupler)

  • Why pair: Combine lipogenesis inhibition (CMS121) with energy-expenditure activation (BAM15) for multi-axis metabolic read-out.

NMN (Nicotinamide Mononucleotide)

  • Why pair: Mitochondrial/NAD⁺ pathway + lipid metabolism modulation may produce layered bioenergetic outcomes.

SLU-PP-332 (Pan-ERR Agonist)

  • Why compare: Exercise-mimetic vs lipogenesis suppression—contrast different metabolic entry-points in obesity/aging studies.

Known Concerns (Context)

  • Pre-clinical tool compound: While CMS121 has entered Phase 1 (safety) studies, therapeutic use is not established—use in research context only. 
  • Target breadth: Modulating ACC1/FASN affects multiple lipid pathways—off-target effects and compensatory metabolism may influence results.
  • Model specificity: Many positive findings are in ageing/AD or diet-induced models; translation to other tissues/systems may vary.
  • General: For laboratory research use only; not for human consumption or therapeutic use.

Specifications & Handling

  • Form: Small-molecule solid (lot-coded) — verify free base.
  • Storage: Dry, preferably ≤ −20 °C; protect from light and moisture.
  • In solution: Soluble in DMSO/ethanol; record solvent %, pH, time-to-assay; avoid multiple freeze-thaws.
  • Labeling: Tamper-evident; research-only; lot/SKU clearly displayed.

Regulatory & Use Notice

Sold for laboratory research use only. Not for human consumption, medical, or veterinary use. No human-use instructions are provided. Buyer is responsible for safe handling and regulatory compliance.

CMS121 Research Compound | ACC1 / FASN Lipogenesis Modulator | Neurodegeneration, Metabolic & Ageing Studies

Keywords: CMS121, CMS-121, ACC1 inhibitor, FASN inhibitor, lipogenesis suppression, cognitive decline model, metabolic ageing model, Base Peptides.

You may also like